A two-part phase 1 single-dose trial was conducted between 2012 and 2015 to assess the efficacy of an anti-human IL-31 antibody (BMS-981164) produced by Bristol-Myers Squibb for atopic dermatitis, but the results were never published. The gene discussed is IL31; the disease is atopic eczema.